Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + Veledimex in Pediatric Brain Tumors
NCT03330197Phase 2Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- Sep 2017
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ad-rts-hil-12 in brain tumor, diffuse intrinsic pontine glioma (DIPG), sponsored by Alaunos Therapeutics. Started Sep 2017; status: terminated.
02
Drugs
ad-rts-hil-12
03
Conditions
brain tumordiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03330197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330197.